Clinical trials: Aromatase Inhibitors
Musculoskeletal Symptoms, Breast Cancer
Evaluating the Efficacy of Structured Exercise Interventions in Alleviating Aromatase Inhibitor-Induced Arthralgia in Breast Cancer Survivors: a Pilot Study Protocol
Endocrine therapy represents a foundational approach for managing hormone receptor-positive breast cancer, with treatment typically spanning 5 to 10 years.
- Conditions
- Musculoskeletal Symptoms, Breast Cancer, Endocrine Therapy, Aromatase Inhibitors
- Trial name
- RE-MS (NCT06754293)
- Testing
- rehabilitation exercise
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Fudan University
Musculoskeletal Symptoms, Breast Cancer
AI-based Skeleton Recognition System for Rehabilitation Exercise in Breast Cancer Survivors: A Randomized Controlled Trial
This study aims to develop and evaluate an artificial intelligence (AI)-based skeletal recognition system designed to support real-time, interactive rehabilitation exercise (RE programs.
- Conditions
- Musculoskeletal Symptoms, Breast Cancer, Endocrine Therapy, Aromatase Inhibitors
- Trial name
- AiRE-MS (NCT06642948)
- Testing
- Motor rehabilitation based on ai visual recognition
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Fudan University
Polymorphism, CYP19
Aromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea
Aromatase(CYP19)inhibitor is one of the major antihormonal drug for breast cancer in postmenopausal women. The variation of CYP19 may affect the effect of aromatase inhibitor.
- Conditions
- Polymorphism, CYP19, Aromatase Inhibitor
- Trial name
- CYP19 (NCT01137136)
- Where
- South Korea
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
the Efficacy of Aromatase Inhibitor vs. Gonadotrpins Releasing Hormone Agonists in Treating Premenopausal Women With Uterine Adenomyosis
Aromatase Inhibitors or GnRH-a for Uterine Adenomyosis
To date, there is no uniform agreement on the most appropriate therapeutic methods for managing women with uterine adenomyosis and/or adenomyoma who want to preserve their fertility.
- Trial name
- NCT01218581
- Testing
- received oral letrozole (2.5 mg/day)and goserelin subcutaneosly (3.6 mg/month)
- Where
- Egypt
- Volunteers
- 32 people
- Sponsor
- Mansoura University